Aravive Appoints Rudy Howard as Chief Financial Officer
June 03 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage
oncology company developing targeted therapeutics to treat
metastatic disease, today announced the appointment of Rudy Howard
as Chief Financial Officer, effective today. Vinay Shah has stepped
down as CFO for personal reasons but will remain with the Company
as an advisor to ensure a smooth transition.
“We are pleased to welcome Mr. Howard to our leadership team
during this pivotal time for the Company,” said Gail McIntyre,
Ph.D., DABT, Chief Executive Officer of Aravive. “His financial
experience and expertise will be an asset as we continue to grow
the organization. On behalf of the Aravive team, I’d like to thank
Mr. Shah for his leadership, devotion to Aravive, and many
meaningful contributions to the Company over the years. We wish him
continued success in his future endeavors.”
Prior to joining Aravive, Mr. Howard served as the Chief
Financial Officer of vTv Therapeutics Inc., a clinical-stage
pharmaceutical company listed on the Nasdaq Capital Market (Nasdaq:
VTVT). Prior to joining vTv Therapeutics Inc., he served as the
Chief Financial Officer of SciQuest, Inc., an international
spend-management software company. From November 2008 until joining
SciQuest, Mr. Howard served as Senior Vice President and Chief
Financial Officer of MDS Pharma Services, a pharmaceutical services
company. From 2003 until joining MDS Pharma Services, he operated
his own financial consulting company, Rudy C. Howard, CPA
Consulting, in Wilmington, North Carolina, where his services
included advising on merger and acquisition transactions, equity
and debt issuances and other general management matters. Mr. Howard
additionally served as Chief Financial Officer for PPD, Inc., and
was a partner with PricewaterhouseCoopers. Mr. Howard holds a B.A.
in Accounting from North Carolina State University, and he is a
Certified Public Accountant.
“I am excited to join Aravive at this important stage in the
Company’s growth,” said Mr. Howard. “Aravive has a broad pipeline
of novel, targeted therapeutics being developed to improve the
health and extend the lives of people living with cancer. I look
forward to executing on our strategic and financial objectives as
we advance our pipeline, scale the business, and create value for
patients and shareholders.”
About AraviveAravive, Inc. is a late
clinical-stage oncology company developing targeted therapeutics to
treat metastatic disease. Our lead product candidate, batiraxcept
(formerly AVB-500), is an ultra-high affinity decoy protein that
binds to GAS6, the sole ligand that activates AXL, inhibiting
metastasis, tumor growth, and restoring sensitivity to anti-cancer
agents. Batiraxcept has been granted Fast Track Designation by the
U.S. FDA and Orphan Drug Designation by European Commission in
PROC. Batiraxcept is in an active registrational Phase 3 trial in
platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial
in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2
trial in pancreatic adenocarcinoma (NCT04983407). The Company is
based in Houston, Texas and received a Product Development Award
from the Cancer Prevention & Research Institute of Texas
(CPRIT) in 2016. Additional information at www.aravive.com.
Forward Looking StatementsThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 on our current
expectations and projections about future events. In some cases,
forward-looking statements can be identified by terminology such as
“may,” “should,” “potential,” “continue,” “expects,” “anticipates,”
“intends,” “plans,” “believes,” “estimates,” and similar
expressions and include statements regarding Mr. Howard’s financial
experience and expertise being an asset as the Company continues to
grow the organization, the Company’s broad pipeline of novel,
targeted therapeutics improving the health and extend the lives of
people living with cancer and executing on the Company’s strategic
and financial objectives as the Company advances its pipeline,
scales the business, and creates value for patients and
shareholders. Forward-looking statements are based on current
beliefs and assumptions, are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those contained in any
forward-looking statement as a result of various factors,
including, but not limited to, risks and uncertainties related to:
the contributions to be derived by Mr. Howard, the ability of the
Company’s broad pipeline of novel, targeted therapeutics to improve
the health and extend the lives of people living with cancer, the
ability to execute on the Company’s strategic and financial
objectives as the Company advances its pipeline, scales the
business, and creates value for patients and shareholders, the
ability to enroll the expected number of patients, the impact of
COVID-19 on the Company's clinical strategy, clinical trials,
supply chain and fundraising, the Company's ability to expand
development into additional indications, the Company's dependence
upon batiraxcept, batiraxcept’s ability to have favorable results
in clinical trials, the clinical trials of batiraxcept having
results that are as favorable as those of preclinical and clinical
trials, the ability to receive regulatory approval, potential
delays in the Company's clinical trials due to regulatory
requirements or difficulty identifying qualified investigators or
enrolling patients; the risk that batiraxcept may cause serious
side effects or have properties that delay or prevent regulatory
approval or limit its commercial potential; the risk that the
Company may encounter difficulties in manufacturing batiraxcept; if
batiraxcept is approved, risks associated with its market
acceptance, including pricing and reimbursement; potential
difficulties enforcing the Company's intellectual property rights;
the Company's reliance on its licensor of intellectual property and
financing needs. The foregoing review of important factors that
could cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
risk factors included in the Company's Annual Report on Form 10-K
for the fiscal year ended December 31, 2021 and subsequent filings
with the SEC. Except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking
statement, or to make any other forward-looking statements, whether
as a result of new information, future events or otherwise.
Contact:Marek Ciszewski, J.D.Vice President,
Investor RelationsMarek@Aravive.com(562) 373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024